Norges Bank Krystal Biotech, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $1.74 Million - $2.08 Million	11,340 New	11,340 $2.08 Million
Q4 2023 Feb 09, 2024	BUY	$96.0 - $128.29 $1.09 Million - $1.45 Million	11,340 New	11,340 $1.41 Million
Q3 2023 Nov 13, 2024	BUY	$108.51 - $130.22 $1.97 Million - $2.36 Million	18,136 New	18,136 $2.1 Million
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $1.47 Million - $1.76 Million	-13,526 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$78.48 - $130.32 $533,350 - $885,654	6,796 Added 59.93%	18,136 $2.13 Million
Q1 2023 May 15, 2024	BUY	$72.39 - $84.27 $3.48 Million - $4.05 Million	48,101 New	48,101 $3.85 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $1.46 Million - $1.84 Million	23,083 New	23,083 $1.83 Million
Q3 2022 Nov 13, 2023	BUY	$64.85 - $82.4 $877,161 - $1.11 Million	13,526 New	13,526 $942,000
Q3 2020 Nov 10, 2020	SELL	$37.76 - $48.49 $450,401 - $578,388	-11,928 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$37.03 - $60.0 $441,693 - $715,680	11,928 New	11,928 $494,000
Q2 2020 Aug 07, 2020	SELL	$37.03 - $60.0 $245,545 - $397,860	-6,631 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$35.02 - $65.64 $232,217 - $435,258	6,631 New	6,631 $287,000

311

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.04B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.